A multicentre, randomised, controlled, open-labelled trial of paclitaxel-containing chemotherapy (ATT) followed by CMF versus the same chemotherapy plus Herceptin in women with locally advanced breast cancer and HER2/C-ERBB-2 overexpression and amplification, with a parallel observational study of the same chemotherapy regimen alone, in patients with HER2 negative tumors (0 or 1+ by immunohistochemistry).

Trial Profile

A multicentre, randomised, controlled, open-labelled trial of paclitaxel-containing chemotherapy (ATT) followed by CMF versus the same chemotherapy plus Herceptin in women with locally advanced breast cancer and HER2/C-ERBB-2 overexpression and amplification, with a parallel observational study of the same chemotherapy regimen alone, in patients with HER2 negative tumors (0 or 1+ by immunohistochemistry).

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2014

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Fluorouracil; Methotrexate; Paclitaxel
  • Indications Advanced breast cancer; Breast cancer
  • Focus Therapeutic Use
  • Acronyms NOAH
  • Sponsors Roche
  • Most Recent Events

    • 19 Mar 2014 Results published in the Lancet Oncology.
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 16 Mar 2010 Planned number of patients (332) added as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top